Skip to main content

Table 1 Participant characteristics by cohort (sequencing and replication) and group (control subjects and RRMS patients)

From: Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis

 

Sequencing Cohort

Replication Cohort

  

Control Subjects (n = 9)

RRMS Patients (n = 9)

Control Subjects (n = 18)

RRMS Patients (n = 20)

Female

 

100%

100%

100%

100%

Caucasian

100%

90%

94%

100%

Age (years)

34.75 (±11.45)

42.44 (±9.66)

38.92 (± 9.89)

38.39 (±9.41)

Disease Duration (years)

N/A

15.11 (±11.87)

N/A

9.29 (±.5.52)

EDSS Score

2.00 (±1.32)

2.09 (±1.53)

Age at Onset (years)

27.94 (±8.48)

28.96 (± 8.79)

Number of Relapses

5.98 (±4.91)

6.35 (± 3.33)

Days since Last Relapse

1083.00 (±1271.81)

985 (±969.75)

Treatment

Off Treatment

2

0

Dimethyl fumarate

2

0

Fingolimod

3

10

Natalizumab

2

10

Time on Treatment (years)

2.46 (±2.60)

3.57 (±2.20)

Number of Relapses on Treatment

0.56 (±0.73)

1.50 (±2.12)

Most recent ARCSa

78.33 (±26.76)

81.35 (±20.43)

  1. Except for percentages and absolute numbers, all data is presented as mean (± SD). RRMS relapsing-remitting multiple sclerosis, EDSS extended disability status scale, ARCS audio-recorded cognitive screen, SD standard deviation of the mean. aARCS are only reported for patients who completed an ARCS within a year of sample collection (sequencing cohort n = 3; replication cohort n = 17)